Blockchain
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr. Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. With expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADC), nucleoside/nucleotide drugs, and oligonucleotide drugs (such as RNAi). Additionally, Medicilon has made significant advancements in PROTAC technology and enhanced its BSL-2 laboratory facility.
With the growing pharmaceutical industry and the widespread adoption of artificial intelligence, the market potential for drug discovery is enormous. The addition of Dr. Liu Jian, a seasoned pharmaceutical research scientist, will empower Medicilon Drug Discovery division to revolutionize drug discovery model and bring new imagination to drug discovery.
Dr. Liu Jian obtained his Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA), he subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania. In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA. In 2019, he was awarded the “Outstanding 50 Asian American in Business ” by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New jersey.
With over 20 years of experience in innovative drug development, Dr. Liu Jian has led the team to invent 10 preclinical candidates (PCCs), which have entered Phase I, II, and III clinical trials. He has filed over 72 patent applications, with 21 patents already granted. Dr. Liu Jian also possesses profound academic achievements, having published a total of 47 articles in international academic journals and serving as a reviewer for several international academic journals.
Dr. Liu Jian joined the industry in 2001 and has worked for Merck for nearly 20 years. He has led the R&D of novel small molecule drugs for various diseases, including osteoporosis, obesity, diabetes, cardiovascular disease, cancer, immune disease, antiviral and antibacterial, and pain. Throughout his career, he progressed from Senior Research Chemist to Principal Scientist and External Discovery Chemistry Lead, receiving the “Merck Excellence Award” four times. He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI), leading the development of new drugs for cancer, immune diseases, osteoarthritis, and neurodegenerative diseases. Recently, he became the CEO of Silexon AI, responsible for building the company’s artificial intelligence platform and empowering innovative drug research.
Dr. Liu Jian expressed his honor to be part of Medicilon as President of Drug Discovery Division. Medicilon is known for establishing a comprehensive pharmaceutical preclinical research and development service platform in China and cultivated for 19 years. It has prioritized global cutting-edge technologies and fostered technological innovation. Moving forward, Dr. Liu aims to lead the Drug Discovery Division in efficient and high-quality new drug development. This includes establishing and enhancing various technical platforms for innovative drug research such as AIDD and structural biology, peptide and cyclic peptide drug development, synthetic biology, and nuclear medicine development, realizing Medicilon one-stop service experiment from target research recommendation to IND application, we could empower the discovery of more innovative drugs.
Dr. Chen Chunlin, the Founder and CEO of Medicilon, said, “Welcome Dr. Liu Jian to join Medicilon. We believe that his extensive academic background, outstanding leadership and rich R&D experience will bring Medicilon more professional and cutting-edge innovative drug development technology , as well as advanced industry insights and strategic guidance crucial to Medicilon to next stage of development.
bybit lucky
Blockchain
Blocks & Headlines: Today in Blockchain (BlackRock, Plume, SEALSQ, Hedera, Deutsche Bank, KuCoin)
Blockchain technology continues to drive innovation across industries, reshaping finance, infrastructure, and philanthropy. Today’s news roundup explores exciting developments in blockchain ETFs, tokenization funding, quantum-resistant chips, public blockchain initiatives, and impactful social projects. Here’s a deep dive into the latest blockchain headlines:
BlackRock ETF Embraces Blockchain with First Muni Bond Purchase
BlackRock’s blockchain-focused ETF has made its first foray into municipal bonds, signaling increased confidence in integrating blockchain technology with traditional finance. The ETF’s strategic investment demonstrates how blockchain can enhance transparency and efficiency in bond markets.
By tokenizing municipal bonds, BlackRock aims to simplify trading and settlement processes while reducing associated costs. This development underscores the growing role of blockchain in transforming financial instruments and fostering greater market accessibility.
Source: Yahoo Finance
Plume Secures Funding for Tokenization Platform
Blockchain fintech company Plume has raised significant funding to advance its tokenization platform. The company’s innovative approach enables businesses to convert real-world assets into digital tokens, streamlining asset management and unlocking liquidity.
Tokenization is rapidly gaining traction as a game-changer in sectors such as real estate, art, and commodities. Plume’s success reflects a broader trend of investment in blockchain solutions that bridge the gap between traditional assets and decentralized technologies.
Source: Fortune
SEALSQ and Hedera Partner for Quantum-Resistant Blockchain Chips
SEALSQ and Hedera have announced a groundbreaking collaboration to develop quantum-resistant chips designed to secure blockchain infrastructure. These advanced chips will provide robust protection against future quantum computing threats, ensuring the integrity of blockchain networks.
As quantum computing capabilities evolve, safeguarding blockchain ecosystems becomes increasingly critical. This partnership highlights the importance of proactive measures in maintaining the resilience and trustworthiness of decentralized systems.
Source: The Quantum Insider
Deutsche Bank’s Public, Permissioned Blockchain Initiative
Deutsche Bank’s Layer 2 blockchain solution is set to go public and operate as a permissioned network, according to its tech partner. This initiative aims to strike a balance between accessibility and security, leveraging blockchain to streamline financial services and enhance operational efficiency.
The decision to adopt a public, permissioned model reflects a growing trend among enterprises seeking to harness the benefits of decentralization while maintaining control over sensitive data. Deutsche Bank’s approach could serve as a blueprint for other financial institutions exploring blockchain adoption.
Source: CoinDesk
KuCoin’s “Light Up Africa” Initiative Brings Hope to Thousands
Cryptocurrency exchange KuCoin has made a significant impact through its “Light Up Africa” donation ceremony in Ghana, benefiting 36,000 children across the continent. The initiative combines blockchain technology with philanthropy to address energy poverty and support education.
By leveraging blockchain for transparency in charitable contributions, KuCoin sets an example of how the crypto industry can drive meaningful social change. The project demonstrates the potential of blockchain to empower communities and foster sustainable development.
Source: PR Newswire
Industry Implications and Key Takeaways
Today’s developments highlight the transformative potential of blockchain across multiple domains:
- Integration with Traditional Finance: BlackRock’s ETF underscores the synergy between blockchain and established financial systems.
- Tokenization Trends: Plume’s funding success reflects the growing demand for digital asset solutions.
- Quantum-Resistant Technologies: SEALSQ and Hedera’s partnership addresses emerging cybersecurity challenges.
- Enterprise Blockchain Adoption: Deutsche Bank’s public, permissioned network showcases the adaptability of blockchain in financial services.
- Social Impact: KuCoin’s philanthropic efforts illustrate blockchain’s capacity to drive positive societal outcomes.
The post Blocks & Headlines: Today in Blockchain (BlackRock, Plume, SEALSQ, Hedera, Deutsche Bank, KuCoin) appeared first on News, Events, Advertising Options.
-
Blockchain5 days agoBridging Innovation and Regulation: How Yellow Network is Transforming Non-Custodial Trading in a Pro-Crypto Future
-
Blockchain6 days ago
Prosper Adds 7,000 More ASIC Miners from BITMAIN To Drive Tokenization of Hashrate as Multichain RWA ; Targets 170MW Capacity With New Strategic Round
-
Blockchain Press Releases5 days agoHTX Ventures Identifies Five Rapidly-Growing Sectors in 2024, Expects Positive Crypto Regulations Driven by Trump Next Year
-
Blockchain5 days ago
Blocks & Headlines: Today in Blockchain (Reserve Bank of India (RBI), Aethir, Blockchain Center Abu Dhabi, Qubetics, )
-
Blockchain3 days ago
50,000+ Mined Coins and 100,000 New Users: EMCD Summarizes 2024
-
Blockchain6 days agoLoan Brokers Market Opportunities and Strategies Report to 2033 – Loan Brokers Market Poised for Strong Growth, Forecasted to Reach $947.9 Billion by 2033
-
Blockchain4 days agoBuilding Bridges in Crypto: Bybit Sparked Dialogues and Joined Industry Leaders at Bitcoin MENA
-
Blockchain Press Releases4 days agoDubai Police Team Triumphs at KuCoin Sponsored 2024 Dubai Open Gov Padel Cup
